Companies

ImmuRX

Adimab is changing the discovery, maturation and production of therapeutic human antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. Our proprietary library design and presentation technology allows us to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology.

Adimab was founded by two of the world's leading yeast biotechnologists: Professor Tillman Gerngross (Dartmouth, Co-founder of GlycoFi, Inc., a wholly owned subsidiary of Merck & Co. since 2006) who led the humanization effort to engineer yeast for the production of human glycoproteins, and Professor Dane Wittrup (MIT, Co-founder of Biodisplay, acquired by Abbott Labs in 2001.) who pioneered yeast surface display for the discovery and maturation of antibody fragments.

For more information, visit Adimab, Inc.

Balch Hill Medical, Inc. is working to commercialize medical innovations developed at Dartmouth Hitchcock Medical Center, Dartmouth Medical School and throughout the Dartmouth community. Balch Hill will evaluate new products and organize funding and approvals for those technologies that have commercial potential. The Company uses Dartmouth-based resources and personnel for analysis, trials, administration and technical support to the extent possible. Balch Hill expects to launch its first medical device product in the Fall of 2009.

Website coming soon.

Celdara builds academic and early-stage inventions into high-potential medical companies. CM identifies discoveries and inventions of exceptional value at the earliest stages, engages the inventor and their institution to access the technology, and builds a business around the technology within CM. When successful, we may spin the business out as part of an A-round of financing, or grow it organically into either a source of cash flow or a trade sale target.

For more information, visit www.celdaramedical.com.

Cognitive Electronics is creating new types of microprocessors that will revolutionize the way the world computes. Optimized for parallel processing, Cognitive Electronics technology allows for dramatically better computing performance per watt than technologies on the market today. In fields such as finance, search, defense, biotech, telecom, mobile, and more, Cognitive Electronics is creating greener, faster computing solutions that vastly improve current applications and open up wholly new opportunities that were previously impossible to realize.

Website coming soon.

The Dartmouth Reference Laboratory is a Dartmouth Medical School laboratory established to perform small-volume and esoteric clinical testing in conjunction with Dartmouth-Hitchcock Medical Center. The laboratory also takes part in research projects conducted by DHMC physicians in multiple departments. Clinical assays include therapeutic drug monitoring for transplant patients, tumor markers for oncology patients, inflammatory markers for rheumatology patients, and a variety of other immunoassays.

Website coming soon.

GlycoFi is focussed on creating Next Generation Biotherapeautics with superior pharmaceutical attributes using our proprietary glycan optimizations technology.

For more information, visit www.glycofi.com.

The Institute for Innovative Technology in Medical Education (iInTIME), a not-for-profit organization launched by Dartmouth pediatricians Dr. Leslie Fall and Dr. Norm Berman, was established in 2006 as a proactive response to changing requirements in medical education. The mission of iInTIME is to advance medical education through the collaborative development, maintenance, and research of innovative and comprehensive computer-assisted instruction programs. iInTIME meets its mission through its role as a developer and distributor of virtual patient cases for third year medical students throughout the United States and Canada.

For more infromation, visit iInTIME.

ImmuRX is developing adjuvanct platforms for the treatment of cancer and infectious disease.

ImmuRx is changing the potential of immunotherapy to treat cancer and chronic infectious disease. By stimulating both the innate and adaptive halves of the immune system, ImmuRx has demonstrated significantly greater immune responses and greater therapeutic benefit than most competing adjuvants in a wide variety of disease indications.

ImmuRx’s unique approach reduces solid tumor mass, increases survival times in cutaneous and hematapoietic tumor models and protects against both viral and bacterial infections at levels approaching 100% in numerous animal models. The ‘generic’ nature of the ImmuRx platform allows for broad utility against a wide variety of cancers and infectious diseases.

ImmuRx has assembled a team of leading immunologists, clinical practitioners, intellectual property counsel, and management to bring this discovery to the next stage.

For more information, visit www.immurx.com.

Oncopartners and IBPC (Instituto Brasileiro de Pesquisa em Câncer) have created a new strategy for enhancing global clinical oncology research by providing sponsors with well-controlled access to Brazil’s extensive patient population. As exclusive partners with the premier network of public hospitals in Brazil, Oncopartners is confident that our services and expertise will enable you to significantly increase the enrollment rate for Phase II and III studies and will ensure that data from the Brazilian sites is of the highest quality. Eighty percent of Brazil’s 190 million citizens are served by the public healthcare system. The country’s leading oncologists, highly motivated to participate in research which offers access to treatments and compounds otherwise unavailable through the public system’s formulary, formed IBPC.

Based in various U.S. offices and São Paulo, Brazil, Oncopartners has made significant investments in assembling a team of international industry veterans supported by a customized IT infrastructure, robust SOPs, and active participation by leading oncologists throughout Brazil. We work with our Pharma, Biotech, and CRO clients to identify the best solutions for their specific needs. Oncopartners is able to offer our clients a full suite of site support and clinical development services. Our staff offers unparalleled clinical, regulatory and operational expertise and experience.

For more information, visit oncopartners.com

ProQueSys, LLC

ProQueSys was founded to bring to market a new and powerful data correlation technology, named Process Query Systems. Since the inception of databases, companies have collected every conceivable piece of information with the ultimate objective to make better business decisions based on the stored data. Unfortunately, databases are growing bigger and larger, while the ability to usefully analyze the data in them, has not improved much.

Process Query Systems are generic correlation platforms that enable the user to find patterns in stored data that might not be readily apparent. Specifically, if you have some knowledge of the relationships in the data, a PQS can use this knowledge to find behavioral patterns, and detect changes in behavioral patterns over time, no matter what the data actually is. A PQS is therefore application independent, and can be used for many different data analysis problems.

For more information please email Vince Berk at vberk@proquesys.com or visit www.proquesys.com.

segTEL, Inc.

For more information, visit segTEL, Inc.